E‐E Ke
YOU?
Author Swipe
View article: Targeting Fascin1 maintains chondrocytes phenotype and attenuates osteoarthritis development
Targeting Fascin1 maintains chondrocytes phenotype and attenuates osteoarthritis development Open
Osteoarthritis (OA) is the most common form of arthritic disease, and phenotypic modification of chondrocytes is an important mechanism that contributes to the loss of cartilage homeostasis. This study identified that Fascin actin-bundling…
View article: PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial Open
No direct comparison has been performed between different programmed cell death-1 (PD-1) inhibitors for first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The feasibility of using PD-L1-expression-guided imm…
View article: Genomic and immune characteristics of <i>HER2</i>‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy
Genomic and immune characteristics of <i>HER2</i>‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy Open
The efficacy of immunotherapy in advanced HER2 ‐mutated non‐small‐cell lung cancer (NSCLC) remains incomprehensively studied. A total of 107 NSCLC patients with de novo HER2 mutations were retrospectively studied at Guangdong Lung Cancer I…
View article: Intratumoral genetic and immune microenvironmental heterogeneity in <scp>T4N0M0</scp> (diameter ≥ 7 cm) non‐small cell lung cancers
Intratumoral genetic and immune microenvironmental heterogeneity in <span>T4N0M0</span> (diameter ≥ 7 cm) non‐small cell lung cancers Open
Background Starting with low metastatic capability, T4N0M0 (diameter ≥ 7 cm) non‐small cell lung cancers (NSCLCs) constitute a unique tumor subset, as with a large tumor size but no regional or distant metastases. We systematically investi…
View article: The role of T790M mutation in EGFR-TKI re-challenge for patients with <i>EGFR</i>-mutant advanced lung adenocarcinoma
The role of T790M mutation in EGFR-TKI re-challenge for patients with <i>EGFR</i>-mutant advanced lung adenocarcinoma Open
Epidermal growth factor receptor (EGFR) T790M mutation has shown to be associated with the clinical outcomes of patients after initial EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy in EGFR-mutant advanced non-small cell lung cancer (NS…
View article: Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence
Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence Open
First-line afatinib significantly improved progression-free survival, patient-reported outcomes, and quality of life compared with chemotherapy regimens in patients with advanced epidermal-growth-factor-receptor ( EGFR) mutation-positive n…